Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock. On February 18, 2026, she acquired 8,914 shares at $0.00 per share as an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan. On February 19, 2026, she acquired an additional 1,884 shares of restricted stock at $0.00 per share upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. Following these grants, she directly owned a total of 22,756.061 shares of Encompass Health common stock.
Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported two stock awards. On February 18, 2026, he acquired 17,720 shares of common stock, and on February 19, 2026, he received 2,154 restricted shares. Following these grants, he directly holds 99,584 shares of Encompass Health common stock.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported stock awards in Encompass Health Common Stock. On February 18, 2026, he acquired 37,588 shares as an annual restricted stock award pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan. On February 19, 2026, he acquired an additional 4,430 restricted shares upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. After these grants, his directly held stake increased to 102,353 shares, and the filing also notes indirect holdings through irrevocable trusts and his spouse.
Encompass Health Corp reported stock awards to Chief Accounting Officer Andrew L. Price. He acquired 8,178 shares of Encompass Health common stock on February 18, 2026 and 1,560 shares on February 19, 2026, both at a stated price of $0.00 per share.
The 8,178-share issuance reflects restricted stock delivered after meeting performance criteria from a February 23, 2023 performance share unit award. The 1,560-share grant is an annual restricted stock award under the company’s 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases. On February 19, 2026, he received 12,796 shares of Encompass Health common stock at $0.00 per share, increasing his direct holdings to 490,812 shares. This issuance of restricted stock resulted from meeting performance criteria under a performance share unit award granted on February 23, 2023.
On February 18, 2026, Tarr was also granted 100,946 shares of restricted stock at $0.00 per share, bringing his direct ownership to 478,016 shares immediately after that grant. This award was an annual restricted stock grant made under the corporation's 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported equity awards of company common stock. On February 18, 2026, he acquired 7,690 shares of restricted stock at $0.00 per share as a grant or award. On February 19, 2026, he acquired an additional 1,430 restricted shares at $0.00 per share.
The filing notes that 1,430 shares were issued upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. The 7,690-share transaction is described as an annual restricted stock award under the corporation's 2025 Omnibus Performance Incentive Plan. After these transactions, Fay directly owned over one hundred thousand Encompass Health common shares.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported acquiring company stock through equity awards. On February 18, 2026, he received 10,254 shares of Encompass Health common stock at a price of $0.00 per share as a grant or award, bringing his direct holdings to 26,296 shares.
On February 19, 2026, he received an additional 3,790 restricted shares at $0.00 per share, increasing his direct ownership to 30,086 shares. Footnotes state that one issuance reflects satisfaction of performance criteria from a February 23, 2023 performance share unit award, and the other is an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp. President & CEO Mark J. Tarr, who is also a director, reported multiple open-market sales of company common stock on February 11, 2026.
He sold a total of 150,000 shares at weighted-average prices ranging from $107.47 to $113.58 per share, and directly owned 377,070 shares of Encompass Health common stock after these transactions.
Invesco Ltd. has reported a significant shareholding in Encompass Health Corp. As of 12/31/2025, Invesco, as a parent holding company to its investment advisers, may be deemed to beneficially own 4,972,725 shares of Encompass Health common stock, representing 4.9% of the class.
Invesco has sole voting power over 4,761,846 shares and sole dispositive power over 4,972,725 shares, with no shared voting or dispositive power. The shares are held of record by clients of Invesco’s advisers, and no single individual has more than 5% economic ownership.
Invesco certifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Encompass Health, consistent with a passive investment reported on a Schedule 13G/A.
Encompass Health Corporation has a planned sale of restricted or control securities under Rule 144. The notice covers up to 150000 shares of common stock, with an aggregate market value of 16738961, to be sold through UBS Financial Services Inc. on the NYSE.
The filing states that 100615977 shares of the issuer’s common stock are outstanding. It also shows an acquisition entry where common stock was acquired on 02/17/2020 via RSA vesting from Encompass Health Corporation, with 2514 securities in that transaction.